| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_84f5399462b0a35a02069ae92dee06ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65489661f0066f1d878dfbeb410daf41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f0b99d4f61bc0b60fab6ab5dd24db3c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 |
| filingDate |
2007-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7c4b705bf92446ff1f0414abcd2eadd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7941fa9309027b0231719523bef9665a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f0e6ce0865db4243ded3b7f6d3f8d50 |
| publicationDate |
2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008008854-A9 |
| titleOfInvention |
Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| abstract |
The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors or for the treatment of viral infections. The compounds provided interfere with the binding of SDFl to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis, or for reducing entry of HIV in to a cell while not reducing the capacity of the stem cells to proliferate. The compounds may be useful for long term treatment regimes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8921328-B2 |
| priorityDate |
2006-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |